The biotech firm reported a narrower-than-expected loss and revenue exceeding forecasts by $77.91M for the quarter.
Ionis Pharmaceuticals posted a Q2 GAAP loss per share of $0.69, beating estimates by $0.38. Revenue reached $268M, surpassing expectations by $77.91M despite a 40.7% year-over-year decline.
The company’s revenue grew 56% in Q2 and 69% in the first half of 2026 compared to the same periods last year. Analysts had anticipated weaker performance amid ongoing industry challenges.
Shares may react positively to the earnings beat, though the year-over-year revenue drop remains a key focus for investors.